Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 7 | 2017 | 68 | 0.920 |
Why?
|
| Schizophrenia | 5 | 2014 | 73 | 0.750 |
Why?
|
| Drug Monitoring | 2 | 2014 | 17 | 0.370 |
Why?
|
| Fluvoxamine | 2 | 2006 | 3 | 0.340 |
Why?
|
| Isoxazoles | 1 | 2008 | 11 | 0.320 |
Why?
|
| Piperidines | 1 | 2008 | 76 | 0.310 |
Why?
|
| Benzodiazepines | 2 | 2006 | 13 | 0.280 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 52 | 0.250 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 53 | 0.190 |
Why?
|
| Bupropion | 1 | 2017 | 10 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2007 | 137 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 102 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2017 | 166 | 0.140 |
Why?
|
| Pharmacogenetics | 2 | 2006 | 45 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 195 | 0.130 |
Why?
|
| Thiazoles | 1 | 2014 | 71 | 0.120 |
Why?
|
| Piperazines | 1 | 2014 | 109 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 343 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 217 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 140 | 0.090 |
Why?
|
| Receptors, Adrenergic | 1 | 2008 | 11 | 0.080 |
Why?
|
| Receptors, Dopamine | 1 | 2008 | 21 | 0.080 |
Why?
|
| Receptors, Serotonin | 1 | 2008 | 21 | 0.080 |
Why?
|
| Marketing | 1 | 2008 | 38 | 0.080 |
Why?
|
| Perphenazine | 1 | 2007 | 1 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 109 | 0.080 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2007 | 17 | 0.080 |
Why?
|
| Pituitary Gland | 1 | 2007 | 59 | 0.080 |
Why?
|
| Humans | 10 | 2017 | 34853 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2006 | 1 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 154 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 376 | 0.070 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2006 | 8 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2006 | 11 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 165 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2007 | 1353 | 0.060 |
Why?
|
| Clozapine | 1 | 2004 | 17 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 406 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 82 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2017 | 269 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2005 | 628 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 182 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 465 | 0.050 |
Why?
|
| Middle Aged | 3 | 2017 | 9642 | 0.050 |
Why?
|
| Obesity | 1 | 2007 | 965 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 1268 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 11034 | 0.040 |
Why?
|
| Remission Induction | 1 | 2017 | 18 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 171 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2017 | 93 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 243 | 0.040 |
Why?
|
| Veterans | 1 | 2017 | 115 | 0.040 |
Why?
|
| Comorbidity | 1 | 2017 | 606 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 12 | 0.030 |
Why?
|
| Male | 4 | 2017 | 18870 | 0.030 |
Why?
|
| Animals | 2 | 2008 | 14307 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2017 | 1349 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 901 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 173 | 0.030 |
Why?
|
| Female | 3 | 2017 | 19873 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 2007 | 3 | 0.020 |
Why?
|
| United States | 1 | 2017 | 3894 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 38 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 2007 | 24 | 0.020 |
Why?
|
| Prolactin | 1 | 2007 | 59 | 0.020 |
Why?
|
| Homozygote | 1 | 2007 | 75 | 0.020 |
Why?
|
| Serotonin | 1 | 2007 | 114 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 11 | 0.020 |
Why?
|
| Isomerism | 1 | 2006 | 62 | 0.020 |
Why?
|
| Reference Standards | 1 | 2006 | 52 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 34 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 116 | 0.020 |
Why?
|
| Dopamine | 1 | 2007 | 232 | 0.020 |
Why?
|
| Genotype | 1 | 2007 | 641 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 555 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 841 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1056 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 370 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 1425 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 1534 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1681 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 3261 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 3414 | 0.010 |
Why?
|
| Aged | 1 | 2007 | 6448 | 0.010 |
Why?
|